Prevalence of Metabolic Syndrome Components in an Urban Mexican Sample: Comparison between Two Classifications by Isordia-Salas, Irma et al.
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2012, Article ID 202540, 8 pages
doi:10.1155/2012/202540
Research Article
Prevalence of Metabolic Syndrome Components in an Urban
Mexican Sample: Comparison betweenTwo Classiﬁcations
Irma Isordia-Salas,1 DavidSantiago-Germ´ an,1,2 Helem Rodr` ıguez-Navarro,1
Mart´ ınAlmar´ az-Delgado,3 AlfredoLea˜ nos-Miranda,4 FranciscoAnaya-G´ omez,5
GabrielaBorrayo-S´ anchez,6 andAbraham Majluf-Cruz1
1Unidad de Investigaci´ on M´ edica en Trombosis, Hemostasia y Aterog´ enesis, HGR No. 1 “Dr. Carlos Mac Gregor S´ anchez Navarro”
Instituto Mexicano del Seguro Social, CP 06720, M´ exico, DF, Mexico
2Escuela Nacional de Ciencias Biol´ ogicas, Instituto Polit´ ecnico Nacional, CP 07738, M´ exico, DF, Mexico
3JefedelLaboratorioCl´ ınicodel,HGRNo.1“Dr.CarlosMacGregorS´ anchezNavarro”InstitutoMexicanodelSeguroSocial,CP06720,
M´ exico, DF, Mexico
4UnidaddeInvestigaci´ onM´ edicaenMedicinaReproductiva,UMAEHGO4,InstitutoMexicanodelSeguroSocial,M´ exico,DF,Mexico
5Servicio de Medicina Interna, HGR No. 1 “Dr. Carlos Mac Gregor S´ anchez Navarro” Instituto Mexicano del Seguro Social, CP 06720,
M´ exico, DF, Mexico
6Hospital de Cardiolog´ ıa, Centro M´ edico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, CP 06720, M´ exico, DF, Mexico
Correspondence should be addressed to Irma Isordia-Salas, irmaisordia@yahoo.com.mx
Received 2 July 2011; Revised 11 August 2011; Accepted 25 August 2011
Academic Editor: Jun Ren
Copyright © 2012 Irma Isordia-Salas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. The aim of this study was to examine the prevalence of metabolic syndrome (MS) components in an urban Mexican
sample.Methods.Atotalof854subjectswereincluded.Anthropometric,bloodpressuremeasurements,clinicaldata,andovernight
fasting blood samples were obtained from all subjects. Results. In accordance with deﬁnitions by the American Heart Association/
National Heart, Lung, and Blood Institute (AHA/NHLBI) and the International Diabetes Federation (IDF), the prevalence of MS
among participants was 59.7 and 68.7%, respectively. The prevalence of MS was higher in women and in individuals older than
45 years of age. More than 40% of the subjects fulﬁlled four criterions of MS according to both deﬁnitions. Conclusions.T h e r e
was a high prevalence of MS components in an urban Mexican sample. Therefore, strong strategies had to be developed for early
detection of MS and its components to prevent DMT2 and atherothrombotic complications in these patients.
1.Introduction
he original description of the metabolic syndrome (MS) by
Reaven [1]consistedofabdominalobesity,insulinresistance,
high blood pressure, impaired glucose tolerance or diabetes,
hyperinsulinemiaanddyslipidemiacharacterizedbyelevated
triglyceride, and low HDL concentration. All of the features
described above are risk factors for atherosclerosis, and
thus MS constituted a signiﬁcant risk for atherothrombosis
disease. The World Health Organization in 1998 [2] and the
Adult Treatment Panel III (ATP III) in 2001 standardized the
deﬁnitions of MS [3]. In 2005, The International Diabetes
Federation (IDF) formulated a new deﬁnition of the MS in
a global consensus statement [4] .T h ep r e v a l e n c eo fM Si n
adults varies from one population to another worldwide.
Several studies indicate that, in USA, one-third of adults
[5] with an alarming proportion of adolescents and children
[6, 7] have the MS. Also a high prevalence of MS in
Europe has been demonstrated [8]. It was reported that non-
diabetic subjects under 40 years of age had an MS prevalence
of 14–41%, depending on the age range [8]. In Mexico, sev-
eral studies had documented a high prevalence of MS [9,
10], with an increased tendency due to changes in lifestyle
behavior (overweight and obesity, physical inactivity, high
carbohydrate diets, alcohol, and tobacco consumption) and
genetic predisposition. The prevalence of the components2 Experimental Diabetes Research
of MS is increased in obesity [11] and is associated with
atherothrombotic complications in micro- and macrovas-
cular territories [12, 13]. The syndrome is also stro-
ngly associated with the increased risk of coronary heart dis-
ease and type 2 diabetes mellitus (T2DM) [14–17]. The ab-
normal metabolic state that accompanies diabetes causes
arterial dysfunction. Relevant abnormalities include chronic
hyperglycemia, dyslipidemia, and insulin resistance [18, 19].
Atherothrombotic disease is the leading cause of dead world-
wide and is the result of genetic and environmental factors
[20, 21].
We have previously identiﬁed genetic variants associated
with myocardial infarction and stroke in Mexican young
population,inwhomcomponentsofMSarepresent[22,23].
Therefore, the aim of this study was to examine the preva-
lence of components of syndrome (MS), among Mexican
adult population, and to evaluate the genetic participation in
this group of patients with high vulnerability to T2DM and
atherothrombotic disease.
2.MaterialsandMethods
We conducted a study to identify the prevalence of MS com-
ponents using two deﬁnitions: the IDF and AHA/NHLBI in
an urban Mexican sample from Mexico City. Individuals >20
years of age were invited to participate in the study if they
were interested to know the risk to develop cardiovascular
disease or T2DM. The recruitment period lasted for 1 year
(1 May–30 May 2011). All included subjects provided the
informed written consent to participate in the study.
2.1. Methods. Subjects were interviewed privately by a phy-
sician using pretest questionnaires. The following, demo-
graphic and clinical data were collected at the time of
the interview: sex, age, cigarette smoking previous diseases,
familial history of diabetes, and atherothrombotic disease.
Waistcircumference(WC)wasmeasuredatthemidpoint
between the last rib and the iliac crest with participants
standing and wearing only undergarments. Body weight was
measured by precision scale while subjects were minimally
clothed without shoes. Height was measured in a standing
position without shoes using tape meter while the shoulders
were in a normal state. Body mass index (BMI) was calculat-
ed as weight in kilograms divided by height in meters
squared. Patients were deﬁned as overweight with BMI of
25.0–29.9kg/m2, and obese with a BMI ≥30kg/m2.A l l
measurements were taken by the same person. Blood pres-
sure (at rest) was measured with the participant seated. Two
readings were taken in 5-minute interval between these two
separated measurements, and thereafter the mean of the two
measurements was considered to be the participant’s blood
pressure. The subjects were considered smokers if they were
currently smoking (regularly or occasionally, including also
former smokers deﬁned as people who stopped smoking at
least one year before the examination). A familial history of
atherothrombotic disease was deﬁned as acute myocardial
infarction (AMI), stroke, or sudden death in a ﬁrst-degree
male relative younger than 55 years of age or a female relative
younger than 65 years of age.
2.2. Laboratory Methods. In the morning, after an overnight
fast, venous blood was sampled for the measurements of
the serum glucose, total and HDL cholesterol, triglycerides,
hs-CRP, uric acid, and plasma concentration of ﬁbrinogen.
Plasma low-density lipoprotein (LDL) cholesterol was calcu-
lated with the equation of Friedewald et al. [24], except when
triglycerides exceeded 400mg/dL. Buﬀyc o a tw a sc o l l e c t e d
and frozen for genetic studies.
Plasma levels of LDL, ﬁbrinogen, uric acid, hs-CRP, and
HbA1c were considered high if they were above 160mg/dL,
400mg/dL, 6mg/dL in women and 7mg/dL in men, 3.0mg/
L, and 6.5%, respectively.
The study protocol was reviewed and approved by the
Human Ethical Committee and Medical Research Council
of Instituto Mexicano del Seguro Social and conforms to
the ethical guidelines of the 1975 Declaration of Helsinki.
Informed written consent was obtained from all subjects
before enrollment.
2.3. Diagnostic Criteria of the Metabolic Syndrome. The MS
was deﬁned according to each of the IDF and AHA/NHLBI
deﬁnitions as described in Table 1 [4, 25].
2.4. Statistical Analysis. Continuous data are expressed as
the mean ± standard deviation (SD); categorical data are
expressed with percentages. The signiﬁcance of diﬀerences
between continuous variables was determined by Student’s
t-test. Diﬀerences between categorical variables were deter-
mined with the chi-square test. A P value <0.05 was con-
sidered as statistically signiﬁcant. All statistical analyses were
performed using SPSS (statistical package for the social
sciences) statistical software package (version 16: SPSS Inc,
Chicago, Il, USA).
3. Results
A total of 854 subjects were included in this study (see
Figure 1). To ascertain whether diﬀerent deﬁnitions may
yield diﬀerent prevalence, MS was diagnosed on the bases
of American Heart Association/National Heart, Lung, and
Blood Institute (AHA/NHLBI) and International Diabetes
Federation (IDF) criterions (Table 1).
Table 2 shows demographic, clinical, and biochemical
featuresofsubjectswithMS(MS+),andwithoutMS(MS−).
The metabolic syndrome was identiﬁed in 607 individuals
(407/woman versus 200/men). The mean of age of the sub-
jects MS+ and MS− was similar (53.4 ± 11.0 versus 49.3 ±
13.4, P = 0.43), respectively. The body mass index (BMI)
was MS+ 29.9 ± 4.8 versus MS− 26.7 ± 4.2, P<0.001. There
was a statistical signiﬁcance in terms of waist circumference
(MS+ 97.3 ± 10.8cm versus MS− 88.5 ± 11.5cm) (P =
0.001). There was a higher triglycerides levels in the group of
MS+comparedwithMS−(233.8 ±220.7versus129.0 ±7.3)
(P<0.001). The high-density lipoprotein cholesterol (HDL-
C) was lower in the group of patients with MS (P<0.001).
There was no diﬀerences in total cholesterol between both
groups (P = 0.58). The concentration of ﬁbrinogen, uric
acid, and HbA1c was higher in the group of MS+, compared




Figure 1: Percent of patients with number of criterions based on IDF y AHA/NHBLI deﬁnitions stratiﬁed by sex and age. Regardless of the
severity of the metabolic syndrome, we found that 43.7% of the individuals fulﬁlled four criterions when MS was diagnosed by IDF, and
45.3% of the subjects had three components when was used the AHA/NHLBI deﬁnition. Similar results were found when we did the analysis
stratiﬁed by gender. As we expect, in the analysis stratiﬁed by age-based MS by IDF and AHA/NHLBI deﬁnitions, we found that individuals
≤45 years old fulﬁlled 3 criterions, whereas four components were present in the older group (43.8%).
As it was expected there was a higher frequency of car-
diovascular risk factors such as smoking, hypertension, and
familial history of atherothrombotic disease in the group of
individuals with MS. The prevalence of MS diagnosed based
on IDF, AHA/NHLBI, or combination of both deﬁnitions
was (68.7%, 59.7%, and 57.2%), respectively.
Table 3 showstheanalysisofmetabolicsyndromeaccord-
ing to the IDF deﬁnitions. There was no diﬀerence in
mean of age between men (53.1 ± 9.5 years) and women
(53.7 ± 11.3 years). It was more frequent in women (67.7%)
than in men (32.3%). Reduced HDL cholesterol was more
frequent in woman (93.2%) compared with the group of4 Experimental Diabetes Research
Table 1: Criteria for Clinical diagnosis of the metabolic syndrome by the IDF and AHA/NHLBI deﬁnitions.
The IDF deﬁnition The AHA/NHLBI deﬁnition
Central obesity: deﬁned as waist circumference
≥90cm for Asian men and ≥80cm for Asian woman
plus any two of the following four criteria Three or more of the following
Central obesity: deﬁned as waist circumference
≥102cm for men and ≥88 for woman
Raised fasting plasma glucose (FPG): ≥100mg/dL, Raised fasting plasma glucose (FPG): ≥100mg/dL
or previously diagnosed type 2 diabetes or previously diagnosed type 2 diabetes
Raised triglycerides ≥150mg/dL, Raised triglycerides ≥150mg/dL
or speciﬁc treatment for this lipid abnormality or speciﬁc treatment for this lipid abnormality
Reduced HDL cholesterol: Reduced HDL cholesterol:
<40mg/dL in males and <50mg/dL in females <40mg/dL in males and <50mg/dL in females
Elevated blood pressure ≥130/≥85mm Hg, or Elevated blood pressure ≥130/≥85mm Hg, or
previous medical diagnosis of hypertension previous medical diagnosis of hypertension
Table 2: Demographic, clinical, and biochemical features of subjects with and without metabolic syndrome included in the study.
MS+ MS−
Subjects n (%) 607 (70%) 247 (30%)
Gender n (%)
Man 200 (33.0%) 74 (30.0%)
Women 407 (67.0%) 173 (70.0%)
Age (years) 53.4 ± 11.0 49.3 ± 13.4
Body mass index (kg/m2) 29.9 ± 4.8 26.7 ± 4.2
Waist circumference (cm) 97.3 ± 10.8 88.5 ± 11.5
Triglycerides (mg/dL) 233.8 ± 220.7 129.0 ± 7.3
HDL-C (mg/dL) 36.02 ± 9.0 48.0 ± 13.7
Total cholesterol (mg/dL) 211.8 ± 61.5 205.8 ± 42.4
FPG (mg/dL) 158.3 ± 48.1 94.8 ± 16.9
Fibrinogen (mg/dL) 377.0 ± 89.2 3 69.1 ± 71.5
Uric Acid (mg/dL) 5.4 ± 2.8 3.9 ± 1.3
hs-CRP (mg/dL) 1.02 ± 0.5 0.78 ± 0.22
HbA1c (%) 5.0 ± 2.6 4.3 ± 2.1
Currents smoking n (%) 136 (22.4) 45 (18.2)
Blood pressure ≥130/≥85mmHg or previous diagnosis of hypertension
n (%) 301 (49.58)
Previously diagnosed hypertension n = (%) 282 (46.45) 23 (30.2)
New cases of hypertension n = (%) 19 (3.13)
Elevated fasting glucose ≥100mg/dL or previous diagnosis of T2DM
n (%) 398 (65.56)
Previously T2DM n = (%) 165 (27.18) 33 (30.2)
New cases of T2DM n = (%) 26 (4.28)
No T2MD patients with FPG ≥100mg/dL–125mg/dL n = (%) 209 (34.43)
FH of AT n (%) 112 (18.45) 30 (14.5)
HDL-C = high-density lipoprotein cholesterol, FG = fasting glucose, hsCRP = high sensitivity C protein reactive, HbA1c = glycosylate hemoglobin, T2DM =
type 2 diabetes mellitus, IDF = International Diabetes Federation, AHA/NHLBI = American Heart Association/National Heart, Lung, and Blood Institute, FH
of EAT = familial history of atherothrombosis.
men (90.0%). The prevalence of elevated triglycerides was
similar in both groups. There was a similar percent of indi-
vidualswithelevatedfastingglucose ≥100mg/dLorprevious
diagnosis of T2DM women (64.8%) versus men (67.3%). In
the group of women (64.8%) with the criteria before men-
tioned, 35.8% had glucose level between ≥100mg/dL and
<126/mg/dL, and 29.0% had been already diagnosed with
T2DMwhereas,inthegroupofmen,33.1%had ≥100mg/dLExperimental Diabetes Research 5
Table 3: Prevalence (%) of MS and its components to IDF deﬁnition, by gender.
Measure (any 3 of 5 constitute diagnosis of MS)
Men Women
Total = 587
n = 190 (32.3%) n = 397 (67.7%)
Age (years) 53.1± 53.7±
Waist circumference n (%) 190 (100%) 397 (100%)
Men ≥90cm
Women ≥80cm
Reduced HDL-C n (%) 171 (90.0%) 370 (93.2%)
Men <40mg/dL
Women <50mg/dL
Triglycerides ≥150mg/dL or medical treatment of elevated TG n (%) 142 (74.7%) 293 (73.8%)
Elevated fasting glucose ≥100mg/dL or previous diagnosis of T2DM 128 (67.3 %) 257 (64.8%)
Blood pressure ≥130/≥85mmHg or previous diagnosis of hypertension n (%) 104 (54.7%) 183 (46.1%)
Table 4: Prevalence (%) of MS and its components to AHA/NHLBI deﬁnition, by gender.
Measure (any 3 of 5 constitute diagnosis of MS)
Men Women
Total = 510
n = 155 (30.4) n = 355 (69.6%)
Age (years) 53.6± 53.9±
Reduced HDL-C n (%) 148 (95.5%) 332 (93.5%)
Men <40mg/dL
Women <50mg/dL
Triglycerides ≥150mg/dL or medical treatment of elevated TG n (%) 124 (80.0%) 270 (76.0%)
Elevated fasting glucose ≥100mg/dL or previous diagnosis of T2DM 114 (73.5%) 250 (70.4%)
Blood pressure ≥130/≥85mmHg or previous diagnosis of hypertension n (%) 101 (65.2%) 178 (50.2%)
Waist circumference n (%) 73 (47.0%) 295 (83.0%)
Men ≥102cm
Women ≥88cm
and <126/mg/dL, and 34.2% had been diagnosed with the
disease. Hypertension was more common in men (54.7%)
than in woman (46.1%).
Table 4 shows the MS diagnosed based on AHA/NHLBI
criterions, and low HDL cholesterol was the most common
with a similar frequency in both sexes (men 95.5%) versus
(women 93.5%), followed by increased triglyceride levels
withhigherpercentageinmen(80.0%)andwomen(76.0%).
There was a slightly high percent of individuals with elevated
fasting glucose ≥100mg/dL or previous diagnosis of T2DM
in the group of men (73.5%) versus women (70.4%). Hyper-
tension was the least frequent component with 65.2% in the
group of man versus 50.2% in woman. There was a very
signiﬁcant diﬀerence in waist circumference between both
groups: men (47.0%) versus woman (83%).
Table 5 shows the MS diagnosed based on IDF deﬁnition
and stratiﬁed by age (≤ y >45 years old). There was a higher
percent of men in the group of younger individuals, whereas
the women were the predominant gender in the older group.
Followed by the waist circumference, the reduced HDL-
C was the second most frequent criteria with 94.4% in
individuals ≤45 years old versus >45 years (91.5%). We
found a signiﬁcant diﬀerence in elevated triglycerides levels
between both groups of age, with higher levels in the young
group (83.3%) versus the oldest one (71.6%). In terms of
individuals with previous diagnosis of T2DM or elevated
fastingglucose ≥100mg/dL,therewasahigherpercentinthe
groupofolderindividuals(68.3%)comparedtotheyoungest
one (55.6%). The percent of elevated blood pressure was
higher in the old group against the youngest one (54.9%
versus 27.0%).
Table 6 shows the results of the analysis of individuals
with MS diagnosed based on the AHA/NHLBI stratiﬁed by
age. The female group was predominant in both groups of
age in the group of younger women (61.9%) and (69.4%)
in the oldest one. The most common criterion was reduced
HDL-C with 97.0% in the youngest group versus 93.4% in
the old one. In contrast, as we expected we found elevated
triglycerides levels in both groups, with higher percent in the
group ≤45 years of age (86.1%) compared with the oldest
group (75.0%). There was a slight diﬀerence in the percent
of waist circumference between the groups (≤45 years,
74.3% versus >45 years, 71.6). Increased fasting glucose
≥100mg/dL or previous diagnosis of T2DM was found in
67.3%ofyoungindividualsversus72.4% <45yearsofage.As
itwasexpected,therewasahigherpercentofindividualswith6 Experimental Diabetes Research








Waist circumference n (%) 126 (100) 461(100)
Men ≥90cm, women ≥80cm
Reduced HDL-C n (%) 119 (94.4) 422 (91.5)
Men <40mg/dL
Women <50mg/dL
Triglycerides ≥150mg/dL or medical treatment of elevated TG n (%) 105 (83.3) 330 (71.6)
Elevated fasting glucose ≥100mg/dL or previous diagnosis of T2DM 70 (55.6) 315 (68.3)
Blood pressure ≥130/≥85mmHg or previous diagnosis of hypertension n (%) 34 (27.0) 253 (54.9)








Waist circumference n (%) 75 (74.3) 293 (71.6)
Men ≥102cm, women ≥88cm
Reduced HDL-C n (%) 98 (97.0) 382 (93.4)
Men <40mg/dL
Women <50mg/dL
Triglycerides ≥150mg/dL or medical treatment of elevated TG n (%) 87 (86.1) 307 (75.0)
Blood pressure ≥130/≥85mmHg or previous diagnosis of hypertension n (%) 29 (28.7) 250 (61.1)
Elevated fasting glucose ≥100mg/dL or previous diagnosis of T2DM 68 (67.3) 296 (72.4)
high blood pressure or previous diagnosis of hypertension in
the group of >45 years of age (61.1%) versus (28.7%) in the
youngest group.
We want to point out thatwe identiﬁed an increased level
of fasting overnight glucose ≥100mg/dL and <126mg/dL
in the group of individuals ≤45 years of age when MS was
diagnosed by IDF criterions (38.9%), versus >45 years of age
(33.8%), and when diagnosed by AHA/NHLBI ≤45 years
(46.5%) versus >45 years old (35.5%) (data not shown).
4. Discussion
Patients with MS die from complication of T2DM and ath-
erothrombotic disease such as acute myocardial infarction
andstroke.Inpreviousstudies,ahighfrequencyofmetabolic
syndrome (MS) has been identiﬁed in our population.
Therefore, the aim of this study was to identify phenotypic,
speciﬁc and genotypic proﬁle that may help to improve the
prevention of T2DM, dyslipidemia, and atherothrombotic
complication such as AMI and Stroke. Although the ﬁnal
results with respect to this principal aim are still awaited,
the study clearly conﬁrms that an early screening should be
performed in individuals anticipated to be at risk of T2DM,
dyslipidemia, and obesity by their primary care physician
and should be treated in metabolic syndrome clinic.
The MS was present in 68.7% of the total sample,
according to IDF deﬁnitions versus 59.7%, compared with
AHA/NHLBI. In 57.2% of the individuals the MS was diag-
nosed base by either one deﬁnition IDF or AHA/NHLBI.
We identify more individuals with MS by IDF classiﬁcation
compared to AHA/NHLBI. This result is probable due to
the waist circumference lower cutoﬀ applied by the IDF. In
contrast, by AHA/NHLBI, we found an increased percentage
of individuals with hypertension, dyslipidemia, and high
levels of glucose, compare to IDF classiﬁcation, because the
waist circumference is not an absolute required criterion.
This combination of criterions might represent a diﬀerent
severity of the MS between patients classiﬁed by one or
another.
Those results are in agreement with those previously
reported by Rojas et al. [26], who identiﬁed a less frequency
of the syndrome by AHA/NHLBI compared with IDF in our
population, but are in disagreement with those obtained by
other investigators in American population >20 years [4].Experimental Diabetes Research 7
Anotherrelevantissuefoundinthisstudyisthehighpre-
valence of the numbers of criterions in each subject from this
sample stratiﬁed by groups of age and gender by both clas-
siﬁcations IDF and AHA/NHLBI. In the present study, we
found a high percent of individuals who fulﬁlled four or
morecriterions.However,fortheIDFclassiﬁcation,thewaist
circumference was the most frequent criterion, followed by
lowered HDL-C and increased level of triglycerides, whereas
for the AHA/NHLBI, the more frequent component was
HDL-C,triglycerides,andwaistcircumference.Themostim-
portant is that all three criterions are associated with an
increased risk for cardiovascular disease, and they are fre-
quently present in the same individual.
In approximately 42.2% of the individuals ≤45 years of
age, who were diagnosed with MS by either classiﬁcation,
IDF, or AHA/NHLBI, registered glucose levels were between
≥100mg/dL and 125mg/dL. The most important thing is
that they were not under lowering glucose therapy, because
they did not have a recent blood glucose test.
On the other hand, as we expect there was a higher per-
cent of individuals with T2DM >45 years old (35.7%) com-
pared with the subjects ≤45 years old (18.7%) in both
groups of patients diagnosed with either deﬁnition IDF or
AHA/NHLBI. Those results corroborated that insulin resis-
tance (IR) is more frequent in young individuals, whereas
T2DM is predominant in older individuals. Therefore, an
early detection and lifestyle changes have to be implemented
in young individuals to avoid the development of chronic
disease such as T2DM and atherothrombotic disease com-
plications such acute myocardial infarction and stroke.
Also, similar results were obtained when we analyzed the
t r i g l y c e r i d e sl e v e l sb ya g e .
In 73.97% of individuals with MS diagnosed by either
deﬁnitions, IDF or AHA/NHLBI were found to have an in-
creased triglycerides levels (≥150mg/dL), and HDL-C below
normal ranges was diagnosed. Most of them had history
of dyslipidemia, but only 19.6% were under lowering lipid
therapy. In this particular case is necessary a rigorous and
constant monitoring in patients with previous history of dy-
slipidemia.
Several new features have been added to the syndrome
over time. These include elevated plasminogen activator
inhibitor-1 (PAI-1) and C-reactive protein (CRP) concen-
trations. These features were added on the basis that they
were frequently found in association with the metabolic
syndrome.Thesefeaturesareprobablyrelatedtobothinsulin
resistance and obesity [27]. In the present study, we failed to
identify, an association between high levels of hs-CRP and
MS, and those results are in agreement with those previously
published by Han et al. [28].
Incontrast,wehavepreviouslyreportedthathigherlevels
ofplasmaPAI-1representariskfactorfordevelopmentofST
elevation acute myocardial infarction (STEAMI) [29].
Therefore, the following step will be determinate PAI-1
levels in the same group of patients with MS. Those results
probabley allow us to include a new atherothrombotic mark-
er in this type of patients in our population.
ApreviousstudybyMadrid-Miller[30]explorestheclin-
ical impact of MS in patients with acute coronary syndrome
(ACS).TheMSwasmorefrequentinolderpatientswithACS
and was associated with poorer in-hospital outcomes.
Since most patients with T2DM die from complications
of atherosclerosis, they should receive intense preventive
interventions proven to reduce their cardiovascular risk.
Using the AHA/NHLBI deﬁnitions, MS is present in 82.3
of self-reported coronary heart diseases (CHD), 87.5% of
type 2 diabetes cases, 43.1% self-reported with high triglyc-
erides, 47.6% of subjects with low HDL-cholesterol levels,
and 70.5% of adults with hypertension [26].
That percentage provides a gross estimate of the contri-
bution of MS to the outcomes mentioned above and justiﬁes
the screening of MS components in persons with those con-
ditions. These results will be useful for updating local guide-
lines for the prevention and treatment of speciﬁc chron-
ic disorders, which requires a multidisciplinary team ap-
proach that implements lifestyle changes and a combination
of drugs (when appropriate). The primary goal of clinical
management in individuals with MS is to reduce the risk of
clinical atherosclerosis disease.
Therefore, our data describes the signiﬁcant challenges
that MS represents to our health system. The Mexican health
system should develop speciﬁc management programs for
all identiﬁed cases; failure to identify or treat cases of MS
will result in a considerable increase in new forms of T2DM
and/or CHD.
5. Conclusions
Our results identify that more than 40% of individuals with
MS has four or more criterions, which represent the severity
of the syndrome among urban Mexican sample. Therefore,
strong strategies had to be developed for early detection of
MS and its components in order to prevent DMT2 and athe-
rothrombotic complications in these patients with myocar-
dial infarction and stoke.
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